SCHEMBL5779323

SCHEMBL5779323

CC(C)(CC(O)(C=O)C(F)(F)F)C1Cc2ccccc2O1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC2 O75106 5/20 0.40
MAOA P21397 5/20 0.40
MAOB P27338 5/20 0.40
DAO P14920 1/20 0.40
HIF1A Q16665 6/20 0.35
SSTR4 P31391 1/20 0.35
ACHE P22303 1/20 0.32
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
MPI P34949 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRB2 P47870 1/20 0.31
HRH3 Q9Y5N1 1/20 0.30
GPBAR1 Q8TDU6 1/20 0.30
NISCH Q9Y2I1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5781340 0.80 HIF1A (0.36) AOC2MAOAMAOBDAOHIF1A
SCHEMBL10877666 0.72 HIF1A (0.52) HIF1ASSTR4ACHENPC1HPGD
SCHEMBL8035974 0.69 AOC2 (0.40) AOC2MAOAMAOBDAOHIF1A
SCHEMBL11952613 0.69 SSTR4 (0.41) AOC2MAOAMAOBDAOHIF1A
SCHEMBL12911435 0.69 MAOA (0.41) AOC2MAOAMAOBDAOSSTR4
SCHEMBL7279348 0.68 SSTR4 (0.45) AOC2MAOAMAOBDAOHIF1A
SCHEMBL6473349 0.66 CYP19A1 (0.37) AOC2MAOAMAOBDAOHIF1A
SCHEMBL6477728 0.66 CYP19A1 (0.37) AOC2MAOAMAOBDAOHIF1A
SCHEMBL5777888 0.66 PPARG (0.41) HIF1ASSTR4HPGDTSHRALDH1A1
SCHEMBL3533193 0.66 NR3C2 (0.43) HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638945-A1 HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS Schering Aktiengesellschaft (DE) 2006-03-29 EP disclosed
US-20050090559-A1 Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2005-04-28 US disclosed
WO-2005003098-A1 HETEROCYCLICALLY SUBSTITUTED PENTANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090559-A1 Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents IL1B, NFKBIA, BBOX1 AOC2 2587/4885MAOA 2105/4885MAOB 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.